Bayer Schering Pharma Ag

Schering Aktiengesellschaft

Bayer Intellectual Property Gmbh

Lead Discovery Center Gmbh

Ulrich Luecking

Gerhard Siemeister

Rolf Jautelat

Martin Krueger

Hans Briem

Ingo Hartung

Georg Kettschau

Ulf Boemer

Philip Lienau

Duy Nguyen

Karl-Heinz Thierauch

Anne Mengel

Ulrich Bothe

Jan Eickhoff

Arne Von Bonin

Peter Nussbaumer

Carsten Schultz-Fademrecht

Karl H Thierauch

Axel Choidas

Bert Klebl

Oliver Von Ahsen

Martina Schaefer

Julia Schulze

Wolf-Dietrich Doecke

Gerd Siemeister

Arne Bonin Von

Oliver Ahsen Von

The invention relates to alkynylpyrimidines according to the general formula (I): in which A, R, R, R, R, R, and Rare as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.

Alkynylpyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

The invention relates to substituted sulphoximines according to the general formula (I): in which A, E, G, X, R, R, R, R, R, R, R, R, m, p, q, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted sulphoximines, to methods of preparing said substituted sulphoximines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

Substituted sulphoximines as TIE2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

The invention relates to sulphimides as protein kinase inhibitors of the general formula I 

Sulphimides as protein kinase inhibitors

This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.

N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents

This invention relates to pyrimidine derivatives of general formula I in which Q, R, R, R, R, R, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.

Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents

Macrocyclic pyrimidine derivatives of general formula I in which Rto R, X, Y, A, B, m and n have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinase, their processes for production as well as their use as medications for treating various diseases are described.

Macrocyclic pyrimidines, their production and use as pharmaceutical agents

Growing community of inventors

Berlin, Germany

Ulrich Luecking